podophyllotoxin has been researched along with Vomiting in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (82.35) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrick, B; Clemmons, AB; DeRemer, D; Gandhi, A; Orr, J; Sportes, C | 1 |
| Clark, SM; Clemmons, AB; DeRemer, DL; Garren, J; Kota, VK; Schaack, L | 1 |
| Greco, FA; Hainsworth, JD; Johnson, DH; Wolff, SN | 1 |
| Gordon, EM; Odom, LF | 1 |
| Demitrish, M; Duffin, H; Enochs, K; Groshko, G; Lockhard, C; Maniscalco-Greb, E; Vaughn, CB | 1 |
| Aisner, J; Van Echo, DA; Wiernik, PH | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Kaplan, S; Obrecht, JP; Sonntag, R; Weber, W | 1 |
| Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC | 1 |
| Jankowski, RP; Vahrson, H | 1 |
| Creagan, ET; Eagan, RT; Fleming, TR; Frytak, S; Ingle, JN; Kvols, LK; Rubin, J | 1 |
| Decker, DG; Edmonson, JH; Jorgensen, EO; Malkasian, GD; Webb, MJ | 1 |
| Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH | 1 |
| Amiel, JL; Baron, A; Huguenin, P; Laparre, Ch; Mathé, G; Morin, P; Parrot, R; Pouillart, P; Schwarzenberg, L | 1 |
| Anderson, PN; Baker, LH; Comis, RL; Daniels, JR; Einhorn, LH; Harvey, HA; Issell, BF; Lanzotti, VA; Lawson, RD; Wampler, GL | 1 |
| Einhorn, LH | 1 |
| Bishop, JF; Campbell, JJ; Day, A; Hillcoat, BL; Pepperell, R; Quinn, MA | 1 |
4 trial(s) available for podophyllotoxin and Vomiting
| Article | Year |
|---|---|
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Hig
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Male; Melphalan; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Podophyllotoxin; Vomiting | 2018 |
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation | 1998 |
[The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)].
Topics: Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Nausea; Ovarian Neoplasms; Podophyllotoxin; Remission, Spontaneous; Teniposide; Vomiting | 1977 |
Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
Topics: Adult; Aged; Agranulocytosis; Alopecia; Antineoplastic Agents; Female; Glycosides; Hodgkin Disease; Humans; Lactones; Leukemia; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Nausea; Neoplasms; Neutrophils; Podophyllotoxin; Remission, Spontaneous; Thrombocytopenia; Vomiting | 1973 |
13 other study(ies) available for podophyllotoxin and Vomiting
| Article | Year |
|---|---|
Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
Topics: Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Morpholines; Nausea; Podophyllotoxin; Prospective Studies; Retrospective Studies; Transplantation Conditioning; Vomiting | 2016 |
High-dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Choriocarcinoma; Combined Modality Therapy; Drug Evaluation; Drug Resistance; Dysgerminoma; Etoposide; Female; Humans; Male; Nausea; Neutropenia; Podophyllotoxin; Pregnancy; Teratoma; Vomiting | 1984 |
Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin.
Topics: Alopecia; Child; Child, Preschool; Diarrhea; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Humans; Infant; Infant, Newborn; Leukemia, Monocytic, Acute; Podophyllotoxin; Vomiting | 1984 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Podophyllotoxin; Prednisone; Thrombocytopenia; Vincristine; Vomiting | 1982 |
High-dose VP 16-213 (NSC 141540) for the treatment of patients with previously treated acute leukemia.
Topics: Adult; Antineoplastic Agents; Child; Drug Evaluation; Esophagitis; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Nausea; Pilot Projects; Podophyllotoxin; Vomiting | 1980 |
[Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Topics: Adenocarcinoma; Body Weight; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Leukocyte Count; Lung Neoplasms; Podophyllotoxin; Vomiting | 1981 |
VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Time Factors; Vomiting | 1979 |
Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents.
Topics: Alkylating Agents; Alopecia; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Nausea; Ovarian Neoplasms; Podophyllotoxin; Vomiting | 1978 |
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma; Hematologic Diseases; Humans; Intracranial Pressure; Lomustine; Male; Middle Aged; Nausea; Neoplasm Metastasis; Nitrosourea Compounds; Podophyllotoxin; Teniposide; Vomiting | 1976 |
[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
Topics: Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Neurologic Manifestations; Nitrosourea Compounds; Podophyllotoxin; Vincristine; Vomiting | 1975 |
Multicenter Phase II trial of etoposide in refractory small cell lung cancer.
Topics: Carcinoma, Small Cell; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Multi-Institutional Systems; Nausea; Podophyllotoxin; Vomiting | 1985 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Nausea; Neoplasm Metastasis; Podophyllotoxin; Testicular Neoplasms; Thrombocytopenia; Vomiting | 1986 |
Phase II trial of VP-16-213 in advanced ovarian carcinoma.
Topics: Administration, Oral; Aged; Carcinoma; Cisplatin; Cystadenocarcinoma; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Middle Aged; Nausea; Ovarian Neoplasms; Podophyllotoxin; Vomiting | 1985 |